{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT00495677: Phase 2 Interventional Completed HIV
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PF-232798 is a potent oral CCR5 antagonist with a primary and selectivity/safety pharmacology profile similar to maraviroc (MVC). PF-232798 shows increased binding affinity and improved oral absorption compared to maraviroc. In addition, it retains activity against a laboratory generated maraviroc-resistant HIV-1 strain, indicating an alternative drug resistance profile. PF-232798 binds to the same pocket as MVC within the transmembrane region of CCR5, but shows additional interactions at the ECL2 hinge region. PF-232798 is well tolerated in normal volunteers. PF-232798 had been in a phase-II clinical trial for the treatment of HIV infections. However, this development was discontinued.
Status:
Investigational
Source:
NCT01730768: Phase 2 Interventional Completed Schizophrenia
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00784875: Phase 2 Interventional Completed Primary Insomnia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dimesone is a synthetic glucocorticoid with anti-inflammatory and anti-allergic activity.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gestaclone was developed as a progesterone receptor agonist; however, this compound has never been marketed. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT02467023: Not Applicable Interventional Completed Sepsis
(2015)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT00393120: Phase 2 Interventional Completed HIV Infections
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
INCB9471 is a non-competitive, potent and selective CCR5 small-molecule antagonist patented by pharmaceutical company Incyte Corporation for treatment of human immunodeficiency virus infection. INCB9471 potently inhibited macrophage inflammatory protein-1beta-induced monocyte migration and infection of peripheral blood mononuclear cells by a panel of R5-HIV-1 strains. INCB9471 was shown to be safe and highly efficacious in reducing HIV viral load in phase I and II human clinical trials
Class (Stereo):
CHEMICAL (RACEMIC)
Temiverine was developed as an antimuscarinic and calcium-antagonist agent for the treatment of overactive bladder. Temiverine participated in clinical trials; however, the development of the drug was discontinued on the pre-registration stage.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Hexasonium, an anticholinergic agent, was studied as a spasmolytic. Information about the current use of this drug is not available.
Status:
Investigational
Source:
NCT01106508: Phase 1 Interventional Completed Advanced Solid Tumors
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
NPV-LEQ506 is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. NPV-LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. NPV-LEQ506 is a second-generation inhibitor of smoothened (Smo) with IC50s of 2 and 4 nM in human and mouse, respectively. NPV-LEQ506 has been in clinical trials with Novartis studying the treatment of advanced solid tumors, recurrent or refractory medulloblastoma, and locally advanced or metastatic basal cell carcinoma.
